AstraZeneca joins Boehringer Ingelheim in capping out-of-pocket inhaler costs at $35
Just as insulin manufacturers were pressured into capping monthly out-of-pocket costs, inhaler manufacturers are feeling the same heat. AstraZeneca on Monday joined with Boehringer Ingelheim to cap the price of its blockbuster …